Is There a Role for Triple Therapy After ACS?. [Review]

Is There a Role for Triple Therapy After ACS?. [Review] - 2022

PURPOSE OF REVIEW: The optimal antithrombotic strategy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains the subject of controversy. In this article, we review the current evidence for the use of triple therapy in acute coronary syndrome (ACS) patients. RECENT FINDINGS: The recently published trials of AF patients undergoing PCI have shown that combination of non-vitamin K oral anticoagulants (NOACs) with an antiplatelet agent is either superior or non-inferior to vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) in reducing bleeding complications with no difference in regard to thromboembolic events. Currently, the use of dual therapy (preferably with a NOAC and clopidogrel) is recommended over triple therapy in these patients. The optimal duration should be guided by the assessment of an individual's risk of thrombosis and bleeding events. Copyright (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.


English

10.1007/s11886-022-01634-3 [doi] 10.1007/s11886-022-01634-3 [pii]


*Acute Coronary Syndrome
*Atrial Fibrillation
*Percutaneous Coronary Intervention
Acute Coronary Syndrome/co [Complications]
Acute Coronary Syndrome/dt [Drug Therapy]
Administration, Oral
Anticoagulants/ae [Adverse Effects]
Atrial Fibrillation/co [Complications]
Atrial Fibrillation/dt [Drug Therapy]
Drug Therapy, Combination
Fibrinolytic Agents/ae [Adverse Effects]
Humans
Platelet Aggregation Inhibitors/ae [Adverse Effects]


MedStar Washington Hospital Center


Advanced Cardiac Catheterization Research Fellowship


Journal Article
Review

Powered by Koha